Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  ACADIA Pharmaceuticals Inc.    ACAD

ACADIA PHARMACEUTICALS INC.

(ACAD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

ACADIA Pharmaceuticals : to Announce Fourth Quarter and Full Year 2018 Financial Results on February 26, 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 09:09am EDT

ACADIA to Host Conference Call and Webcast on Tuesday, February 26, 2019, at 5:00 p.m. Eastern Time

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2018 on Tuesday, February 26, 2019, after the U.S. financial markets close. ACADIA’s management will host a conference call and webcast on Tuesday, February 26, 2019, at 5:00 p.m. Eastern Time to discuss ACADIA’s financial results and operations.

The conference call may be accessed by dialing 855-638-4820 for participants in the United States or Canada and 443-877-4067 for international callers (reference passcode 3094204). A telephone replay of the conference call may be accessed through March 12, 2019 by dialing 855-859-2056 for callers in the United States or Canada and 404-537-3406 for international callers (reference passcode 3094204). The conference call also will be webcast live on ACADIA’s website, www.acadia-pharm.com under the investors section and will be archived there until March 26, 2019.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and is commercializing the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. In addition, ACADIA has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, schizophrenia inadequate response, schizophrenia-negative symptoms, major depressive disorder and Rett syndrome. This press release and further information about ACADIA can be found at: www.acadia-pharm.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements regarding the timing of future events. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development, approval and commercialization. For a discussion of these and other factors, please refer to ACADIA’s annual report on Form 10-K for the year ended December 31, 2017 as well as ACADIA’s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACADIA PHARMACEUTICALS INC
04/17ACADIA PHARMACEUTICALS : to Announce First Quarter 2019 Financial Results on May..
BU
04/11ACADIA PHARMACEUTICALS : Supports Parkinson's Disease Awareness Month and World ..
BU
04/02ACADIA PHARMACEUTICALS : to Present at the 18th Annual Needham Healthcare Confer..
BU
04/01ACADIA PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K..
AQ
04/01ACADIA PHARMACEUTICALS : Announces Promotion of Elena Ridloff, CFA to Executive ..
BU
03/28ACADIA PHARMACEUTICALS INC. : - Positive Phase 2 Study Results of Trofinetide in..
AQ
03/27ACADIA PHARMACEUTICALS : Positive Phase 2 Study Results of Trofinetide in Pediat..
BU
03/06ACADIA PHARMACEUTICALS INC : Other Events (form 8-K)
AQ
03/04ACADIA PHARMACEUTICALS : to Present at the Cowen and Company 39th Annual Health ..
BU
02/27ACADIA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condi..
AQ
More news
Financials ($)
Sales 2019 292 M
EBIT 2019 -271 M
Net income 2019 -265 M
Finance 2019 278 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 10,7x
EV / Sales 2020 7,48x
Capitalization 3 393 M
Chart ACADIA PHARMACEUTICALS INC.
Duration : Period :
ACADIA Pharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACADIA PHARMACEUTICALS INC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 32,1 $
Spread / Average Target 36%
EPS Revisions
Managers
NameTitle
Stephen R. Davis Chief Executive Officer & Director
Srdjan R. Stankovic President
Stephen R. Biggar Chairman
Elena H. Ridloff Chief Financial Officer
Randall Owen Chief Medical Officer & SVP-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
ACADIA PHARMACEUTICALS INC.45.83%3 393
IQVIA HOLDINGS INC14.50%26 285
CELLTRION, INC.--.--%22 914
LONZA GROUP16.76%21 810
INCYTE CORPORATION16.31%15 847
EXACT SCIENCES CORPORATION46.13%11 596